

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 8 FEB 10 COMPENDEX reloaded and enhanced
NEWS 9 FEB 11 WTEXTILES reloaded and enhanced
NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS
patent records provide insights into related prior
art
NEWS 11 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 12 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text
applications and grants
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role
for nanomaterial substances
NEWS 21 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 24 APR 07 STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:32:09 ON 21 APR 2009

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:32:22 ON 21 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2009 HIGHEST RN 1137276-53-9

DICTIONARY FILE UPDATES: 20 APR 2009 HIGHEST RN 1137276-53-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10595891narrow.str



```

chain nodes :
11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
3-13 9-11 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
3-13 5-7 6-10 7-8 8-9 9-10 9-11 13-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :

```

G1:N,CH

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom


```

L1 STRUCTURE UPLOADED

```

=> d 11
L1 HAS NO ANSWERS
L1 STR

```



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:32:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3299 TO ITERATE

60.6% PROCESSED 2000 ITERATIONS

12 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 62535 TO 69425

PROJECTED ANSWERS: 129 TO 661

L2 12 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:32:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 66812 TO ITERATE

100.0% PROCESSED 66812 ITERATIONS

290 ANSWERS

SEARCH TIME: 00.00.01

L3 290 SEA SSS FUL L1


=> d scan

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl-

MF C27 H30 N2 O3


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl)methyl]-3-ethyl-
 MF C32 H42 N4 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-
 MF C18 H13 Cl N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl-
 MF C18 H14 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-2-naphthalenylmethyl]-
 MF C30 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

185.88

TOTAL

SESSION

186.10

FILE 'CAPLUS' ENTERED AT 16:33:02 ON 21 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2009 VOL 150 ISS 17
FILE LAST UPDATED: 20 Apr 2009 (20090420/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:32:09 ON 21 APR 2009)

FILE 'REGISTRY' ENTERED AT 16:32:22 ON 21 APR 2009

L1 STRUCTURE UPLOADED
L2 12 S L1
L3 290 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:33:02 ON 21 APR 2009

=> s l3

L4 18 L3

=> s l4 and (pry<2007)

5386808 PRY<2007

L5 11 L4 AND (PRY<2007)

=> d 1-11 ibib abs hitstr

L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1361172 CAPLUS

DOCUMENT NUMBER: 148:33513

TITLE: Preparation of
N-[4-(naphthylalkyl)benzoyl]- β -alanine compounds
and analogs as glucagon receptor antagonists

INVENTOR(S): Kim, Ronald M.; Parmee, Emma R.; Tan, Qiang; Yang,
Cangming; Lins, Ashley Rouse

PATENT ASSIGNEE(S): Merck & Co., Inc., USA


SOURCE: PCT Int. Appl., 76pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

OTHER SOURCE(S): MARPAT 148:33513
GI



959121-79-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-[4-(naphthylalkyl)benzoyl]- β -alanine compds. and analogs as glucagon receptor antagonists useful in treatment and prevention of type 2 diabetes mellitus and related diseases)

RN 959121-76-7 CAPLUS

CN β -Alanine, N-[4-[(1R)-1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959121-77-8 CAPLUS


CN β -Alanine, N-[4-[(1S)-1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959121-78-9 CAPLUS

CN Benzoic acid, 4-[1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959121-79-0 CAPLUS

CN Benzoic acid, 4-[1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]- (CA INDEX NAME)



L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523430 CAPLUS

DOCUMENT NUMBER: 143:60003

TITLE: Preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors

INVENTOR(S): Mabire, Dominique Jean-Pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054210	A1	20050616	WO 2004-EP13164	20041118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295059	A1	20050616	AU 2004-295059	20041118 <--
CA 2546657	A1	20050616	CA 2004-2546657	20041118 <--
EP 1709012	A1	20061011	EP 2004-819602	20041118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1890224	A	20070103	CN 2004-80035857	20041118 <--
BR 2004016532	A	20070109	BR 2004-16532	20041118 <--
JP 2007513101	T	20070524	JP 2006-541830	20041118 <--
IN 2006DN03071	A	20070810	IN 2006-DN3071	20060529 <--
US 20070129375	A1	20070607	US 2006-596086	20060530 <--
MX 2006006255	A	20060809	MX 2006-6255	20060602 <--
KR 2006118534	A	20061123	KR 2006-711234	20060608 <--
NO 2006003028	A	20060628	NO 2006-3028	20060628 <--
PRIORITY APPLN. INFO.:			EP 2003-78859	A 20031205 <--
			WO 2004-EP13164	W 20041118 <--

OTHER SOURCE(S): CASREACT 143:60003; MARPAT 143:60003

GI



AB The title compds. I [$n = 0-2$; $X = N$, CR5; $R_5 = H$ or taken together with R_1 may form $CH:CHCH:CH$; $R_1 = \text{alkyl}$, thienyl; $R_2 = H$, OH, or taken together with R_3 or R_4 may form O; $R_3 = OH$, OR8, SR9, etc.; $R_8 = \text{alkyl}$, alkylcarbonyl, dialkylaminoalkyl; $R_9 = \text{dialkylaminoalkyl}$; $R_4 = H$, alkyl, furanyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from 1-(4-amino-3-nitrophenyl)-2-methyl-1-propanone, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 854523-82-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854523-82-3 CAPLUS

CN Formamide, N-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-phenylpropyl]- (CA INDEX NAME)




IT 854524-08-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854524-08-6 CAPLUS

CN 2(1H)-Quinolinone, 3-methyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523424 CAPLUS

DOCUMENT NUMBER: 143:60001

TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors

INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054201	A1	20050616	WO 2004-EP13163	20041118 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004295058	A1	20050616	AU 2004-295058	20041118 <--
CA 2546300	A1	20050616	CA 2004-2546300	20041118 <--
EP 1687277	A1	20060809	EP 2004-819601	20041118 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1882547	A	20061220	CN 2004-80034176	20041118 <--
BR 2004016206	A	20061226	BR 2004-16206	20041118 <--
JP 2007511574	T	20070510	JP 2006-540338	20041118 <--
SG 150533	A1	20090330	SG 2009-1197	20041118 <--
US 20070072842	A1	20070329	US 2006-595891	20060518 <--
IN 2006DN02813	A	20070803	IN 2006-DN2813	20060518 <--
MX 2006005687	A	20060817	MX 2006-5687	20060519 <--
KR 2006115393	A	20061108	KR 2006-710201	20060525 <--
NO 2006002894	A	20060809	NO 2006-2894	20060620 <--
PRIORITY APPLN. INFO.:			WO 2003-EP13028	A 20031120 <--
			EP 2003-78860	A 20031205 <--
			WO 2003-EP130	A 20031120 <--
			WO 2004-EP13163	W 20041118 <--
OTHER SOURCE(S):	CASREACT 143:60001; MARPAT 143:60001			
GI				



AB The title compds. I [$n = 0-2$; $X = N, CR_7$; $R_7 = H$ or taken together with R_1 may form $CH:CHCH:CH$; $R_1 = \text{alkyl, thiophenyl}$; $R_2 = H, OH, \text{alkyl, alkynyl}$ or taken together with R_3 may form O ; $R_3 = OH, OR_{10}, SR_{11}, \text{etc.}$; $R_{10}, R_{11} = CHO, \text{alkyl, (alkyl)amino, etc.}$; $R_4-R_6 = H, \text{halo, trihalomethyl, etc.}$; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from bromobenzene and 3-methyl-6-quinolinecarboxaldehyde, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 854532-59-5P 854532-61-9P 854533-52-1P

854533-95-2P 854534-00-2P 854534-03-5P


854534-17-1P 854534-18-2P 854534-19-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854532-59-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]-3-ethyl- (CA INDEX NAME)




RN 854532-61-9 CAPLUS

CN 6-Quinolineacetonitrile, 1,2-dihydro-3-methyl-2-oxo- α -phenyl- (CA INDEX NAME)




RN 854533-52-1 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidiny)phenylmethyl]- (CA INDEX NAME)




RN 854533-95-2 CAPLUS

CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)




RN 854534-00-2 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(hydroxyphenylmethyl)- (CA INDEX NAME)



RN 854534-03-5 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-17-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-18-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-19-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylidenemethyl]-3-ethyl- (CA INDEX NAME)




IT 130346-68-8P 130346-69-9P 854532-58-4P
854532-60-8P 854532-62-0P 854532-63-1P
854532-64-2P 854532-65-3P 854532-66-4P
854532-67-5P 854532-69-7P 854532-70-0P
854532-71-1P 854532-72-2P 854532-73-3P
854532-74-4P 854532-75-5P 854532-76-6P
854532-77-7P 854532-78-8P 854532-79-9P
854532-80-2P 854532-81-3P 854532-82-4P
854532-83-5P 854532-84-6P 854532-85-7P
854532-86-8P 854532-87-9P 854532-89-1P
854532-92-6P 854532-93-7P 854532-94-8P
854532-95-9P 854532-96-0P 854532-97-1P
854532-98-2P 854533-00-9P 854533-02-1P
854533-04-3P 854533-06-5P 854533-07-6P
854533-09-8P 854533-14-5P 854533-16-7P
854533-18-9P 854533-20-3P 854533-21-4P
854533-23-6P 854533-25-8P 854533-27-0P
854533-29-2P 854533-30-5P 854533-31-6P
854533-32-7P 854533-33-8P 854533-34-9P
854533-35-0P 854533-36-1P 854533-37-2P
854533-38-3P 854533-39-4P 854533-40-7P
854533-41-8P 854533-42-9P 854533-43-0P
854533-44-1P 854533-45-2P 854533-46-3P
854533-47-4P 854533-48-5P 854533-49-6P
854533-51-0P 854533-53-2P 854533-54-3P
854533-55-4P 854533-56-5P 854533-57-6P
854533-58-7P 854533-59-8P 854533-60-1P
854533-62-3P 854533-65-6P 854533-67-8P
854533-69-0P 854533-71-4P 854533-73-6P
854533-75-8P 854533-79-2P 854533-81-6P
854533-83-8P 854533-85-0P 854533-87-2P
854533-89-4P 854533-91-8P 854533-93-0P
854533-97-4P 854533-98-5P 854533-99-6P
854534-01-3P 854534-02-4P 854534-04-6P
854534-05-7P 854534-06-8P 854534-07-9P
854534-08-0P 854534-09-1P 854534-10-4P
854534-11-5P 854534-12-6P 854534-13-7P
854534-14-8P 854534-15-9P 854534-16-0P
854534-20-6P 854534-21-7P 854534-22-8P
854534-23-9P 854534-24-0P 854534-25-1P
854534-26-2P 854534-27-3P 854534-28-4P
854534-29-5P 854534-30-8P 854534-31-9P
854534-32-0P 854534-33-1P 854535-35-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and
2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 130346-68-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl-
(CA INDEX NAME)




RN 130346-69-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-58-4 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[(methylamino)phenylmethyl]- (CA INDEX NAME)



RN 854532-60-8 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(acetyloxy)phenylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-62-0 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 854532-63-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(dimethylamino)phenylmethyl]-3-methyl- (CA INDEX NAME)




RN 854532-64-2 CAPLUS

CN Urea, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N'-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 854532-65-3 CAPLUS

CN Acetamide, N-[2-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-2-phenylethyl]- (CA INDEX NAME)




RN 854532-66-4 CAPLUS


CN 2(1H)-Quinolinone, 6-(methoxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854532-67-5 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-1H-imidazol-5-yl)phenylmethyl]-
 (CA INDEX NAME)



RN 854532-69-7 CAPLUS
 CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-ethyl- (CA
 INDEX NAME)




RN 854532-70-0 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-
 piperidiny]phenylmethyl]- (CA INDEX NAME)



RN 854532-71-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-
 2-propen-1-yl]-4-piperidiny]methyl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854532-72-2 CAPLUS

CN Piperidinium, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]-1,1-bis[(2E)-3-phenyl-2-propen-1-yl]-, chloride (1:1) (CA INDEX NAME)


Double bond geometry as shown.




● Cl⁻

RN 854532-73-3 CAPLUS


CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)




RN 854532-74-4 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 854532-75-5 CAPLUS
 CN Formamide, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)



RN 854532-76-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-77-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-78-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-79-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854532-80-2 CAPLUS


CN 2(1H)-Quinoxalinone, 3-methyl-6-[phenyl[[3-(2-thienyl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-81-3 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[[3-(1H-pyrrol-1-yl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-82-4 CAPLUS
 CN Acetamide, N-[2-[[[1,2-dihydro-3-methyl-2-oxo-6-quinolinyl]phenylmethyl]amino]ethyl]- (CA INDEX NAME)




RN 854532-83-5 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[phenyl[[3-(1-piperidinyl)propyl]amino]methyl]- (CA INDEX NAME)




RN 854532-84-6 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[[[3-oxo-3-phenylpropyl]amino]phenylmethyl]- (CA INDEX NAME)




RN 854532-85-7 CAPLUS
 CN 2(1H)-Quinolinone, 6-[[2-(dimethylamino)ethoxy]phenylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-86-8 CAPLUS
 CN 2(1H)-Quinolinone, 6-[[2-(2-hydroxyethyl)amino]phenylmethyl]-3-methyl- (CA INDEX NAME)




RN 854532-87-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 854532-89-1 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperidinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1


CRN 854532-88-0
 CMF C32 H41 N3 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 854532-92-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854532-93-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 854532-94-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[2-fluoro-4-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854532-95-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-[3-(dimethylamino)propoxy]phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854532-96-0 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854532-97-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-oxo-1-piperidiny)methyl]-3-ethyl-
(CA INDEX NAME)



RN 854532-98-2 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)phenylmethyl]- (CA
INDEX NAME)




RN 854533-00-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-
piperidiny)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (1:3) (CA
INDEX NAME)

CM 1

CRN 854532-99-3


CMF C31 H40 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-02-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-(cyclohexylmethyl)-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-01-0


CMF C31 H39 N3 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 854533-04-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[6-fluoro-3-(4-piperidinyl)-1H-indazol-1-yl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-06-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-05-4


CMF C32 H42 N4 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 854533-07-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-09-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-14-5 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]phenylmethyl]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-13-4


CMF C31 H33 F N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-16-7 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-[phenyl[[3-(1-piperidinyl)propyl]amino]methyl]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-15-6


CMF C25 H32 N4 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-18-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-(1-piperidinyl)propyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-17-8


CMF C28 H35 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-20-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[1-(phenylmethyl)-3-piperidinyl]amino]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-19-0


CMF C32 H35 N3 O3




CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 854533-21-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-23-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)


CM 1

CRN 854533-22-5
 CMF C24 H28 N2 O4



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 854533-25-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-24-7
CMF C28 H32 N4 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 854533-27-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-[methyl(phenylmethyl)amino]propyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)


CM 1

CRN 854533-26-9
CMF C31 H35 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 854533-29-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[(2-methoxyethyl)amino]phenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-28-1


CMF C21 H24 N2 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 854533-30-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-31-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-32-7 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-2-naphthalenylmethyl]- (CA INDEX NAME)




RN 854533-33-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-34-9 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-chloro-3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-35-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,4-dimethylphenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-36-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[[4-(dimethylamino)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-37-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-38-3 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 854533-39-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,4-difluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-40-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[[2-chloro-5-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-41-8 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-42-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-43-0 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[4H-1,2,4-triazol-4-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)





RN 854533-44-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,6-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-45-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-46-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-1-naphthalenylmethyl]- (CA INDEX NAME)




RN 854533-48-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-oxo-1-piperidiny)methyl]-3-ethyl-
(CA INDEX NAME)



RN 854533-49-6 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-51-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[[2-(dimethylamino)ethoxy][3-(trifluoromethyl)phenyl]methyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854533-50-9


CMF C23 H25 F3 N2 O2



CM 2



CRN 144-62-7

CMF C2 H2 O4




RN 854533-53-2 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl](2-methylphenyl)methyl]- (CA INDEX NAME)




RN 854533-54-3 CAPLUS


CN 2(1H)-Quinolinone, 6-[(3,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-55-4 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-oxo-1-piperidiny]phenylmethyl]- (CA INDEX NAME)




RN 854533-56-5 CAPLUS
 CN 6-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -phenyl- (CA INDEX NAME)




RN 854533-57-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidiny]methyl]-3-ethyl- (CA INDEX NAME)




RN 854533-58-7 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidiny][3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 854533-59-8 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidiny)phenylmethyl]- (CA INDEX NAME)



RN 854533-60-1 CAPLUS
 CN 2(1H)-Quinolinone, 3-methyl-6-[1-phenyl-3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 854533-62-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)propyl]-3-ethyl- (CA INDEX NAME)




RN 854533-65-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]propyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 854533-64-5

CMF C23 H25 F3 N2 O




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854533-67-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-phenylpropyl]-3-ethyl- (CA INDEX NAME)




RN 854533-69-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1-piperidinylmethyl)- (CA INDEX NAME)




RN 854533-71-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-73-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 854533-75-8 CAPLUS
 CN Formamide, N-[(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)




RN 854533-79-2 CAPLUS
 CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methylphenyl)methyl]- (CA INDEX NAME)



RN 854533-81-6 CAPLUS
 CN Formamide, N-[1,3-benzodioxol-5-yl(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-83-8 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(formylamino)methyl]-, ethyl ester (CA INDEX NAME)




RN 854533-85-0 CAPLUS

CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 854533-87-2 CAPLUS

CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 854533-89-4 CAPLUS

CN Formamide, N-[3-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-1-phenylpropyl]- (CA INDEX NAME)




RN 854533-91-8 CAPLUS

CN Formamide, N-[(3-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-93-0 CAPLUS


CN Formamide, N-[(4-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)




RN 854533-97-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[hydroxy(3-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 854533-98-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)



RN 854533-99-6 CAPLUS
 CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)hydroxymethyl]-, ethyl ester (CA INDEX NAME)




RN 854534-01-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-methyl- (CA INDEX NAME)




RN 854534-02-4 CAPLUS

CN 2(1H)-Quinolinone, 6-(1-hydroxy-1-phenyl-2-propyn-1-yl)-3-methyl- (CA INDEX NAME)




RN 854534-04-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-05-7 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854534-06-8 CAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-oxo-2-phenylethyl)- (CA INDEX NAME)




RN 854534-07-9 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-cyclohexyl-1-piperazinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-08-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[3-(4-chlorophenyl)-3-(1H-imidazol-1-yl)propyl]-3-ethyl- (CA INDEX NAME)




RN 854534-09-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)



RN 854534-10-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[1-(4-chlorophenyl)-2-(3-ethyl-1,2-dihydro-2-oxo-6-quinoxaliny)ethyl]- (CA INDEX NAME)




RN 854534-11-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-12-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)(4-methyl-1H-imidazol-1-yl)methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-13-7 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-14-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1-piperidin-1-ylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-15-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-
 (CA INDEX NAME)



RN 854534-16-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl-
 (CA INDEX NAME)




RN 854534-20-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-21-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-piperidinylidene)methyl]-3-ethyl- (CA INDEX NAME)




RN 854534-22-8 CAPLUS

CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinylidene)phenylmethyl]- (CA INDEX NAME)



RN 854534-23-9 CAPLUS


CN 2(1H)-Quinolinone, 5-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-(dimethylamino)-1-propen-1-yl]-3-methyl- (CA INDEX NAME)



RN 854534-24-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-25-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(4-chlorophenyl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-26-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-27-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1E)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 854534-28-4 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1Z)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-29-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-30-8 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-31-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-32-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(1R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 854534-33-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[(1S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 854535-35-6 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



IT 854534-37-5P 854534-38-6P 854534-40-0P

854534-42-2P 854534-48-8P 854534-49-9P


854534-50-2P 854534-51-3P 854534-52-4P

854534-53-5P 854534-62-6P 854534-64-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 854534-37-5 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-methyl- (CA INDEX NAME)




RN 854534-38-6 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N-methyl- (CA INDEX NAME)




RN 854534-40-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxymethyl]-3-ethyl- (CA INDEX NAME)




RN 854534-42-2 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-ethyl- (CA INDEX NAME)



RN 854534-48-8 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-49-9 CAPLUS
 CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl


RN 854534-50-2 CAPLUS
 CN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-51-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-(2-amino-1-phenylethyl)-3-methyl- (CA INDEX NAME)




RN 854534-52-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-(hydroxyphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 854534-53-5 CAPLUS
 CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-62-6 CAPLUS
 CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-ethyl- (CA INDEX NAME)



RN 854534-64-8 CAPLUS
 CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-(4-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:430796 CAPLUS



DOCUMENT NUMBER: 141:7139

TITLE: Preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis

INVENTOR(S): Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng; Brittelli, David R.; Burke, Michael J.; Chen, Gang;

Cook, James; Dumas, Jacques; Sibley, Robert; Turner, Michael R.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 217 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043950	A1	20040527	WO 2003-US36003	20031110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505819	A1	20040527	CA 2003-2505819	20031110 <--
AU 2003290744	A1	20040603	AU 2003-290744	20031110 <--
EP 1565455	A1	20050824	EP 2003-783328	20031110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016169	A	20050927	BR 2003-16169	20031110 <--
CN 1738814	A	20060222	CN 2003-80108639	20031110 <--
JP 2006509840	T	20060323	JP 2005-507146	20031110 <--
MX 2005004779	A	20050722	MX 2005-4779	20050504 <--
US 20060004011	A1	20060105	US 2005-534215	20050506 <--
NO 2005002796	A	20050609	NO 2005-2796	20050609 <--
PRIORITY APPLN. INFO.:			US 2002-425490P	P 20021112 <--
			US 2003-460915P	P 20030407 <--
			US 2003-484202P	P 20030630 <--
			WO 2003-US36003	W 20031110 <--
OTHER SOURCE(S):			MARPAT 141:7139	
GI				



AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF3, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy, amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO2, NH2, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thienyl, pyrrolyl, pyrimidinyl,

oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with angiogenesis (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).

IT 694531-84-5P 694531-85-6P 694531-86-7P
694531-93-6P 694532-04-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiproliferative and angiogenesis inhibitor; preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis)

RN 694531-84-5 CAPLUS


CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 694531-85-6 CAPLUS

CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)




RN 694531-86-7 CAPLUS


CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-piperidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-93-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694532-04-2 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-amino-2-(7-benzoyl-3,4-dihydro-3-oxo-2-quinoxaliny)- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:796538 CAPLUS
 DOCUMENT NUMBER: 139:323440
 TITLE: Preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomography.
 INVENTOR(S): Lesage, Anne Simone Josephine; Bischoff, Francois Paul; Janssen, Cornelus Gerardus Maria; Lavreysen, Hilde
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2003082350	A2	20031009	WO 2003-EP3240	20030326 <--
WO 2003082350	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479109	A1	20031009	CA 2003-2479109	20030326 <--
AU 2003226737	A1	20031013	AU 2003-226737	20030326 <--
AU 2003226737	B2	20080904		
BR 2003008945	A	20050104	BR 2003-8945	20030326 <--
EP 1492571	A2	20050105	EP 2003-745282	20030326 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1642580	A	20050720	CN 2003-807387	20030326 <--
JP 2005524679	T	20050818	JP 2003-579882	20030326 <--
NZ 535438	A	20060831	NZ 2003-535438	20030326 <--
IN 2004DN02631	A	20050401	IN 2004-DN2631	20040908 <--
US 20060083676	A1	20060420	US 2004-509069	20040924 <--
US 7517517	B2	20090414		
MX 2004009435	A	20050125	MX 2004-9435	20040928 <--
ZA 2004007820	A	20051011	ZA 2004-7820	20040928 <--
NO 2004004635	A	20041027	NO 2004-4635	20041027 <--
PRIORITY APPLN. INFO.:			EP 2002-76254	A 20020329 <--
			WO 2003-EP3240	W 20030326 <--
OTHER SOURCE(S):	MARPAT 139:323440			
GI				



AB Radiolabeled title compds. [I, II; X = O, S, C(R₆)₂, NR₇; Y = O, S; R₁ = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, thienyl, quinolinyl, etc.; R₂ = H, halo, cyano, alkyl, amino, heterocyclyl, etc.; R₃, R₄ = H, halo, OH, cyano, alkyl, alkoxy, etc.; R₂R₃ = (CH₂)₃₋₆, Z₄CH₂CH₂CH₂, Z₄CH₂CH₂, etc.; Z₄ = O, S, SO₂, NR₁₁; R₁₁ = H, alkyl, PhCH₂, alkoxycarbonyl; R₃R₄ = (CH₂)₄, CH:CHCH:CH; R₅ = H, cycloalkyl, piperidinyl, oxothienyl, tetrahydrothienyl, aralkyl, alkoxyalkyl, etc.; R₆ = H, aryl, alkyl, aminoalkyl; R₇ = amino, OH], were prepared Most preferred are radiolabeled compds. in which the radioactive isotope is selected from ³H, ¹¹C and ¹⁸F. The invention also relates to their use in a diagnostic

method, in particular for marking and identifying a mGluR1 receptor in biol. material, as well as to their use for imaging an organ, in particular using positron emission tomog. (PET). Thus, title compound (III) was prepared by tritiation of the corresponding bromide in THF using tritium gas and Pd/C catalyst. The purified product showed specific activity of 25 Ci/mmol.


IT 409344-47-4P 409344-48-5P 409344-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomog.)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:275968 CAPLUS

DOCUMENT NUMBER: 136:309857



TITLE: Preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists

INVENTOR(S): Mabire, Dominique Jean-Pierre; Venet, Marc Gaston; Coupa, Sophie; Poncelet, Alain Philippe; Lesage, Anne Simone Josephine

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028837	A1	20020411	WO 2001-EP11135	20010925 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421782	A1	20020411	CA 2001-2421782	20010925 <--
AU 2001093847	A	20020415	AU 2001-93847	20010925 <--
BR 2001014253	A	20030701	BR 2001-14253	20010925 <--
EP 1332133	A1	20030806	EP 2001-974298	20010925 <--
EP 1332133	B1	20080709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002167	A2	20031028	HU 2003-2167	20010925 <--
JP 2004510764	T	20040408	JP 2002-532423	20010925 <--
NZ 524945	A	20050128	NZ 2001-524945	20010925 <--
EE 200300126	A	20050415	EE 2003-126	20010925 <--
CN 1703403	A	20051130	CN 2001-816717	20010925 <--
AU 2001293847	B2	20070524	AU 2001-293847	20010925 <--
AT 400558	T	20080715	AT 2001-974298	20010925 <--
ES 2309095	T3	20081216	ES 2001-974298	20010925 <--
KR 818965	B1	20080404	KR 2003-702014	20030211 <--
HR 2003000229	A1	20030630	HR 2003-229	20030324 <--
IN 2003MN00328	A	20050211	IN 2003-MN328	20030324 <--
BG 107672	A	20040130	BG 2003-107672	20030326 <--
ZA 2003002515	A	20040630	ZA 2003-2515	20030331 <--
NO 2003001474	A	20030505	NO 2003-1474	20030401 <--
NO 325079	B1	20080128		
MX 2003002907	A	20030624	MX 2003-2907	20030401 <--
US 20040082592	A1	20040429	US 2003-381987	20030814 <--
US 7115630	B2	20061003		
US 20050209273	A1	20050922	US 2005-133678	20050520 <--
PRIORITY APPLN. INFO.:			EP 2000-203419	A 20001002 <--
			WO 2001-EP11135	W 20010925 <--
			US 2003-381987	A3 20030814 <--
OTHER SOURCE(S):			MARPAT 136:309857	
GI				



AB The title compds. [I or II; X = O, C(R₆)₂; (wherein R₆ = H, aryl, alkyl, etc.); R₁ = alkyl, aryl, thienyl, etc.; R₂ = H, halo, CN, etc.; R₃, R₄ = H, alkyl; or R₂ and R₃ may be taken together to form (CH₂)₃, (CH₂)₄, CH:CHCH:CH, etc.; or R₃ and R₄ may be taken together to form CH:CHCH:CH, (CH₂)₄; R₅ = H, cycloalkyl, piperidinyl, etc.; Y = O, S; or Y and R₅ may be taken together to form CH:NN, N:NN, NCH:CH], useful for treating or preventing glutamate-induced diseases of the central nervous system, were prepared. Thus, reacting cis-III [R = Cl] with SnMe₄ in the presence of Pg(PPh₃)₄ in PhMe afforded 17% cis-III [R = Me] which showed antagonism at a dose of 2.5 mg/kg bodyweight in cold allodynia test in rats with a Bennett ligation.


IT 409344-47-4P 409344-48-5P 409344-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists)


RN 409344-47-4 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)




RN 409344-48-5 CAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:672545 CAPLUS

DOCUMENT NUMBER: 129:275932

ORIGINAL REFERENCE NO.: 129:56265a,56268a

TITLE: Preparation of 3-oxadiazolylquinoxaline derivatives having affinity to benzodiazepine receptor

INVENTOR(S): Ohno, Kazunori; Odai, Osamu; Furukawa, Kiyoshi; Oka, Makoto

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842701	A1	19981001	WO 1998-JP827	19980227 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2002241379	A	20020828	JP 1997-87646	19970321
AU 9861179	A	19981020	AU 1998-61179	19980227 <--
PRIORITY APPLN. INFO.:			JP 1997-87646	A 19970321 <--
			WO 1998-JP827	W 19980227 <--
OTHER SOURCE(S):			MARPAT 129:275932	
GI				



AB Novel 3-oxadiazolylquinoxaline derivs. represented by general formula (I;


wherein Het is oxadiazolyl; R1 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, lower alkenyl, lower alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkoxy; R2 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, halogeno, hydroxy, lower alkoxy, cyano, nitro, acyl, optionally substituted benzoyl, amino, lower mono- or dialkylamino, lower alkoxycarbonylmethyloxy, lower mono- or dialkylaminocarbonylmethyloxy, or optionally substituted benzyloxy; and R3 is hydrogen, lower alkyl, lower cycloalkyl, halogeno, or lower alkoxy), which are useful as a medicine, in particular, which have a selective affinity for benzodiazepine receptors and are useful as a brain activator and a remedy for senile dementia and Alzheimer's disease. Thus, a solution of 1,2-dihydro-2-oxo-3-quinoxalinecarboxylic acid and N,N'-carbonyl diimidazole in DMF was heated with stirring for 3 h at 60°, followed by adding acetamidoxime, and the stirring was continued for another 1.5 h to give 52.6% the title compound (II; R1 = Me; R2 = H). The latter compound and I (R1 = Et, R2 = OMe) inhibited the binding of [3H]diazepam to synaptosome membrane fraction prepared from rat brain with IC50 of 11.5 and 1.41 nM, resp.

IT 213743-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazolylquinoxaline derivs. having affinity to benzodiazepine receptor as brain activators and remedies for senile dementia and Alzheimer's disease)

RN 213743-73-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:210752 CAPLUS

DOCUMENT NUMBER: 128:257445

ORIGINAL REFERENCE NO.: 128:50967a, 50970a

TITLE: Preparation of indolylbenzoquinoxalinones and related compounds as protein kinase C inhibitors.

INVENTOR(S): Bergstrand, Hakan; Karabelas, Kostas; Sjo, Peter

PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813368	A1	19980402	WO 1997-SE1582	19970919 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
 US, UZ, VN, YU, ZW
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

IN 1997DE02638	A	20050311	IN 1997-DE2638	19970916 <--
TW 472045	B	20020111	TW 1997-86113549	19970918 <--
ZA 9708469	A	19980325	ZA 1997-8469	19970919 <--
CA 2265854	A1	19980402	CA 1997-2265854	19970919 <--
AU 9744775	A	19980417	AU 1997-44775	19970919 <--
AU 716279	B2	20000224		
EP 929551	A1	19990721	EP 1997-943259	19970919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 334531	A	20000929	NZ 1997-334531	19970919 <--
US 6271231	B1	20010807	US 1997-981266	19971218 <--
US 20010025043	A1	20010927	US 2001-865231	20010525 <--
PRIORITY APPLN. INFO.:			SE 1996-3505	A 19960925 <--
			SE 1997-2747	A 19970718 <--
			WO 1997-SE1582	W 19970919 <--
			US 1997-981266	A3 19971218 <--

OTHER SOURCE(S): MARPAT 128:257445
 GI



I

AB Title compds. [I; A, X, Y, Z = C, N; ≥ 2 of A, X, Y, Z = C; may be substituted and/or annulated; excluding 3-(1H-indol-3-yl)-1H-quinoxalin-2-one, 3-(2-methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one], were prepared as protein kinase C inhibitors (no data). Thus, 1,2-phenylenediamine was stirred overnight with [1-[3-(1,3-dioxoisindol-2-yl)propyl]-1H-indol-3-yl]oxoacetic acid 2,5-dioxopyrrolidin-1-yl ester (preparation given) in THF to give 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate. The latter was stirred with MeNH₂ in THF/H₂O to give 3=[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate.


IT 205377-77-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolylbenzoquinoxalinones and related compds. as protein kinase C inhibitors)

RN 205377-77-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-6-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 205377-76-0

CMF C26 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:527663 CAPLUS

DOCUMENT NUMBER: 125:167994

ORIGINAL REFERENCE NO.: 125:31485a,31488a

TITLE: Preparation of
6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-
quinolin(thi)ones for treatment of keratinization
disorders

INVENTOR(S): Venet, Marc Gaston; Mabire, Dominique Jean-Pierre;
Sanz, Gerard Charles

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620200	A1	19960704	WO 1995-EP5173	19951221 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1995CA01685	A	20050304	IN 1995-CA1685	19951220 <--
CA 2207268	A1	19960704	CA 1995-2207268	19951221 <--
AU 9644362	A	19960719	AU 1996-44362	19951221 <--
AU 698199	B2	19981029		
EP 800524	A1	19971015	EP 1995-943237	19951221 <--
EP 800524	B1	20011031		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE

CN 1171789	A	19980128	CN 1995-197162	19951221 <--
CN 1085668	C	20020529		
JP 10511654	T	19981110	JP 1995-520222	19951221 <--
BR 9510504	A	19990601	BR 1995-10504	19951221 <--
RU 2165419	C2	20010420	RU 1997-112898	19951221 <--
AT 207924	T	20011115	AT 1995-943237	19951221 <--
PT 800524	T	20020429	PT 1995-943237	19951221 <--
ES 2166838	T3	20020501	ES 1995-943237	19951221 <--
PL 182956	B1	20020531	PL 1995-321041	19951221 <--
ZA 9510989	A	19970627	ZA 1995-10989	19951227 <--
IL 116577	A	20000229	IL 1995-116577	19951227 <--
US 5922734	A	19990713	US 1997-860239	19970616 <--
FI 9702794	A	19970627	FI 1997-2794	19970627 <--
NO 9703029	A	19970627	NO 1997-3029	19970627 <--
NO 311220	B1	20011029		
PRIORITY APPLN. INFO.:			EP 1994-203773	A 19941228 <--
			WO 1995-EP5173	W 19951221 <--
OTHER SOURCE(S):		MARPAT 125:167994		
GI				



AB Title compds. [I; R = 3-(F3C)C6H4][II; R1 = H, NH2, alkyl; R2,R3 = H, halo, alkyl; X = O or S; 1 of Z1,Z2 = N and the other = CH] were prepared. Thus, (R)-II (R1-R3 = H, X = O, Z1 = N, Z2 = CH) gave complete suppression of estradiol undecylate-induced vaginal keratinization in 50% of ovariectomized rats at 1.25mg/kg orally.


IT 180421-65-2P 180421-66-3P 180421-67-4P
 180421-68-5P 180421-69-6P 180421-70-9P
 180421-71-0P 180421-72-1P 180421-73-2P
 180421-74-3P 180421-75-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders)

RN 180421-65-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 180421-66-3 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 180421-67-4 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-68-5 CAPLUS
 CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 180421-69-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[fluoro-1H-1,2,4-triazol-1-yl][3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-70-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 180421-71-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 180421-72-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)




RN 180421-73-2 CAPLUS

CN 2(1H)-Quinolinone, 8-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 180421-74-3 CAPLUS

CN 2(1H)-Quinolinone, 5-chloro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-75-4 CAPLUS

CN 2(1H)-Quinolinone, 8-fluoro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:612014 CAPLUS

DOCUMENT NUMBER: 113:212014
ORIGINAL REFERENCE NO.: 113:35835a,35838a
TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines,
-quinazolines, and -quinoxalines as drugs
INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston;
Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard
Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 371564	A2	19900606	EP 1989-203014	19891128 <--
EP 371564	A3	19910529		
EP 371564	B1	19950712		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5028606	A	19910702	US 1989-434957	19891113 <--
US 5037829	A	19910806	US 1989-435120	19891113 <--
CA 2002864	A1	19900529	CA 1989-2002864	19891114 <--
CA 2002864	C	19991116		
DK 8905994	A	19900530	DK 1989-5994	19891128 <--
DK 172748	B1	19990628		
NO 8904734	A	19900530	NO 1989-4734	19891128 <--
NO 174509	B	19940207		
NO 174509	C	19940518		
AU 8945646	A	19900607	AU 1989-45646	19891128 <--
AU 620946	B2	19920227		
HU 52498	A2	19900728	HU 1989-6220	19891128 <--
HU 205106	B	19920330		
ZA 8909076	A	19910731	ZA 1989-9076	19891128 <--
SU 1780536	A3	19921207	SU 1989-4742543	19891128 <--
IL 92486	A	19930708	IL 1989-92486	19891128 <--
ES 2088889	T3	19961001	ES 1989-203014	19891128 <--
FI 101964	B	19980930	FI 1989-5687	19891128 <--
FI 101964	B1	19980930		
CN 1042912	A	19900613	CN 1989-108925	19891129 <--
CN 1033752	C	19970108		
JP 02223579	A	19900905	JP 1989-307793	19891129 <--
JP 2916181	B2	19990705		
US 5151421	A	19920929	US 1991-672298	19910320 <--
US 5185346	A	19930209	US 1991-704746	19910523 <--
US 5268380	A	19931207	US 1992-973871	19921110 <--
US 5441954	A	19950815	US 1993-131817	19931005 <--
CN 1106004	A	19950802	CN 1994-117801	19941102 <--
CN 1036002	C	19971001		
CN 1106005	A	19950802	CN 1994-117802	19941102 <--
CN 1036003	C	19971001		
US 5612354	A	19970318	US 1995-409551	19950323 <--
PRIORITY APPLN. INFO.:			GB 1988-27820	A 19881129 <--
			GB 1988-27821	A 19881129 <--
			GB 1988-27822	A 19881129 <--
			US 1989-434205	B2 19891113 <--
			US 1989-434957	A3 19891113 <--
			US 1991-704746	A3 19910523 <--
			US 1992-973871	A3 19921110 <--
			US 1993-131817	A3 19931005 <--
OTHER SOURCE(S):	MARPAT 113:212014			


GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl] were prepared as retinoic acid metabolism inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70° with BzCl in DMF containing AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOCl2 in THF and the product II (R1 = Me, R2 = Cl) stirred overnight at 60-70° with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at ≥10 ng/mL in rats 2 h after oral administration of 40 mg/kg.

IT 120067-41-6P 130344-00-2P 130344-01-3P
 130344-02-4P 130344-03-5P 130346-18-8P
 130346-22-4P 130346-25-7P 130346-26-8P
 130346-27-9P 130346-30-4P 130346-42-8P
 130346-51-9P 130346-66-6P 130346-68-8P
 130346-69-9P 130347-21-6P 130347-22-7P
 130347-23-8P 130347-25-0P 130347-26-1P
 130347-28-3P 130347-30-7P 130347-31-8P
 130347-33-0P 130347-35-2P 130347-37-4P
 130347-39-6P 130347-41-0P 130347-42-1P
 130347-44-3P 130347-45-4P 130347-46-5P
 130347-47-6P 130347-48-7P 130347-62-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as retinoate metabolism and aromatase inhibitor)


RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-00-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-01-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-02-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130344-03-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130346-18-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)




RN 130346-22-4 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)




RN 130346-25-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
 (CA INDEX NAME)



RN 130346-26-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
 (CA INDEX NAME)




RN 130346-27-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
 (CA INDEX NAME)




RN 130346-30-4 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-

(CA INDEX NAME)




RN 130346-42-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130346-51-9 CAPLUS

CN 2(1H)-Quinoxalinone, 6-((1H-imidazol-1-yl)phenylmethyl)-3-phenyl- (CA INDEX NAME)




RN 130346-66-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-68-8 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 130346-69-9 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130347-21-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-22-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-23-8 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)




RN 130347-25-0 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, 4-oxide
 (CA INDEX NAME)




RN 130347-26-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA
 INDEX NAME)



RN 130347-28-3 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-
 methylpropyl)- (CA INDEX NAME)




RN 130347-30-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-
 (CA INDEX NAME)




RN 130347-31-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-33-0 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 130347-35-2 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)




RN 130347-37-4 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-
(CA INDEX NAME)




RN 130347-39-6 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)




RN 130347-41-0 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130347-42-1 CAPLUS


CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-
(CA INDEX NAME)




RN 130347-44-3 CAPLUS
 CN 2(1H)-Quinoxalinone, 3-benzoyl-6-(1H-imidazol-1-ylphenylmethyl)-, 4-oxide
 (CA INDEX NAME)




RN 130347-45-4 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
 INDEX NAME)




RN 130347-46-5 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
 INDEX NAME)




RN 130347-47-6 CAPLUS
 CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA
 INDEX NAME)



RN 130347-48-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-phenyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 130347-62-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3,4-dichlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:407401 CAPLUS

DOCUMENT NUMBER: 111:7401

ORIGINAL REFERENCE NO.: 111:1422h,1423a

TITLE: Imidazole- or pyridine-containing carbostyrils as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors, their preparation, and pharmaceuticals containing them

INVENTOR(S): Walker, Keith A. M.; Bruno, John J.; Martinez, Gregory R.

PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA

SOURCE: U.S., 20 pp.
CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792561	A	19881220	US 1986-868845	19860529
US 4921862	A	19900501	US 1988-247134	19880921 <--
PRIORITY APPLN. INFO.:			US 1986-868845	A3 19860529 <--
OTHER SOURCE(S):	CASREACT 111:7401; MARPAT 111:7401			
GI				



AB Title compds. I [X = R1CR2, cis- or trans-CR3:CR4; R1 = H when R2 = OH, or R1 = Ph, phenylalkyl when R2 = H, OH; Ph is optionally monosubstituted; or R1R2 = O, C1-6 alkylidene, (substituted) benzylidene; R3 = H, C1-6 alkyl; R4 = H; R3R4 = bond; n = 0-3; R = 1-imidazolyl; dotted line = optional covalent bond] are prepared as thromboxane synthetase and cAMP phosphodiesterase inhibitors for treatment of disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels (no data). A mixture of CuI 11.6, (Ph3P)2PdCl2 86, N-propargylimidazole (preparation given) 774 mg, and 6-bromo-3,4-dihydrocarbostyril 1.5 g was stirred in 10mL pyridine and 2 mL triethylamine at 100° for 48 h under N. The reaction mixture was then treated with saturated aqueous K2CO3, extracted with 10% MeOH in CH2Cl2,

and


worked up to give 6-[3-(imidazol-1-yl)-1-propyn-1-yl]-3,4-dihydrocarbostyril. The latter (502 mg) was stirred under H in the presence of 200 mg 10% Pd/C to give 6-[3-(imidazol-1-yl)propyl]-3,4-dihydrocarbostyril (II). A tablet was formulated containing II 25, cornstarch 20, spray-dried lactose 153, and Mg stearate 2 mg.

IT 120067-41-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cAMP phosphodiesterase and thromboxane synthetase inhibitors)

RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
------------------	---------------

FULL ESTIMATED COST

65.28	251.38
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-9.02	-9.02

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 16:34:10 ON 21 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Apr 17, 2009 (20090417/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.35

251.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-9.02

STN INTERNATIONAL LOGOFF AT 16:37:05 ON 21 APR 2009